Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine has now returned with a vengeance. Our to-do list is quickly piling up with deadlines, meetings, and the usual whatnot. We trust you can relate. So to cope, please join us for a few cups of needed stimulation. Our flavor today is Rain Forest Nut, for those keeping track. Meanwhile, here are some tidbits. Hope you have a smashing day and do stay in touch …
GlaxoSmithKline chairman Philip Hampton has begun the process of seeking a new chief executive to succeed Andrew Witty, although a change is not expected before 2017, The Telegraph writes. The move comes following calls by some shareholders to revamp strategy and sell off certain businesses, such as the HIV unit. But Glaxo has privately argued that a diversified portfolio is a buffer against “increased macroeconomic uncertainty.”
Valeant Pharmaceuticals chief executive Michael Pearson has returned following a medical leave and board member Robert Ingram was named chairman, according to this statement. As a result, the drug maker is rescheduling plans to discuss preliminary fourth quarter 2015 results, as well as a business review and updated guidance for the year. The drug maker is also withdrawing its previous financial guidance.
About the Author Reprints
